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Background: There is ongoing debate regarding the optimal sequence of sentinel lymph
node (SLN) biopsy and neoadjuvant chemotherapy (CTX) for breast cancer. We report the
accuracy of comprehensive pre–neoadjuvant CTX and post–neoadjuvant CTX axillary stag-
ing via ultrasound imaging, fine-needle aspiration (FNA) biopsy, and SLN biopsy.
Methods: From 2001 to 2004, 91 neoadjuvant CTX patients at the University of Michigan
Comprehensive Cancer Center underwent axillary staging by ultrasonography, ultrasound-
guided FNA biopsy, SLN biopsy, or a combination of these.
Results: Axillary staging was pathologically negative by pre–neoadjuvant CTX SLN biopsy
in 53 cases (58%); these patients had no further axillary surgery. In 38 cases (42%), axillary
metastases were confirmed at presentation by either ultrasound-guided FNA or SLN biopsy.
These 38 patients underwent completion axillary lymph node dissection (ALND) after delivery
of neoadjuvant CTX. Follow-up lymphatic mapping was attempted in 33 of these cases, and
the SLN was identified in 32 (identification rate, 97%). One third of these cases were com-
pletely node negative on ALND. Residual metastatic disease was identified in 22 cases, and the
SLN was falsely negative in 1 (4.5%).
Conclusions: Patients receiving neoadjuvant CTX can have accurate axillary nodal staging
by ultrasound-guided FNA or SLN biopsy. In cases of documented axillary metastasis at
presentation, repeat axillary staging with SLN biopsy can document the post–neoadjuvant
CTX nodal status. This strategy optimizes pre–neoadjuvant CTX and post–neoadjuvant CTX
staging information by distinguishing the patients who are node negative at presentation from
those who have been downstaged to node negativity and offers the potential for avoiding
unnecessary ALNDs in both of these patient subsets.
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Recent years have seen striking modifications in
the surgical management of breast cancer. Most
notable has been the introduction in the mid 1990s of
sentinel lymph node (SLN) biopsy,1–3 which has re-
placed conventional axillary lymph node dissection
(ALND) as the initial procedure of choice in many
institutions for the accurate staging of breast cancer.
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Despite varying lymphatic mapping techniques used
worldwide, identification rates remain consistently
higher than 91%, with false negatives estimated at
8%4; with more extensive experience, these rates ap-
proach 100%5–7 and <5%,7,8 respectively. A patho-
logically negative SLN is now widely accepted as
reliably identifying the node-negative breast cancer
patient who does not need to face the morbidity of a
standard ALND. It should be noted, however, that
data continue to mature from long-term prospective
trials regarding outcomes in patients treated by SLN
biopsy alone.9
The past 10 years have also witnessed the expan-
sion of neoadjuvant chemotherapy (CTX) programs.
Although induction CTX is the standard of care for
patients with locally advanced breast cancer, the
advantages of primary breast tumor downstaging,
with improved eligibility for breast-conservation
therapy and the ability to more rapidly assess
chemosensitivity, have motivated the development of
protocols that offer primary systemic therapy to pa-
tients with earlier-stage, operable breast cancer as
well. An area of persistent controversy has been how
to optimally integrate SLN biopsy into the neoadju-
vant CTX treatment sequence: should the staging
SLN biopsy be performed before or after the delivery
of induction CTX? Potential concerns with either
approach involve lymphatic mapping accuracy in
patients with relatively larger T2 and T3 tumors, the
effect of CTX on intramammary lymphatics, and ef-
fect of CTX on axillary nodal metastases.
The earliest reported studies involved performing
the SLN biopsy after the delivery of neoadjuvant
CTX, concomitantly with the definitive local breast
therapy and in conjunction with a standard ALND.
These studies have demonstrated mixed results, with
false-negative rates ranging from 0% to 33%, and the
effects of a significant learning curve can be seen.10–15
Many clinicians remain dissatisfied with the available
data on the accuracy of post–neoadjuvant CTX SLN
biopsy and have opted instead for a staging SLN
biopsy performed before delivery of the neoadjuvant
CTX. The primary disadvantages to this approach,
however, are the requirement for an additional sur-
gical procedure at the time of presentation and the
fact that the patients identified as being node positive
by this pre-CTX SLN biopsy are then committed to
undergoing the completion ALND, thereby negating
some of the benefits of CTX downstaging.
Our institution sought to address this issue with a
comprehensive approach to the axilla that uses
ultrasound nodal imaging and lymphatic mapping in
the pre–neoadjuvant CTX and post–neoadjuvant
CTX setting. With this strategy, we specifically eval-
uated the accuracy of lymphatic mapping performed
after the delivery of neoadjuvant CTX in patients
who had pathologically proven axillary metastases at
presentation on the basis of either an ultrasound-
guided fine-needle aspiration (FNA) or a SLN biopsy
performed at the time of diagnosis.
METHODS
From March 2001 to May 2004, 91 patients with
stage I, II, or IIIA breast cancers registered in a
prospectively maintained breast cancer database
underwent pre–neoadjuvant CTX axillary staging at
the University of Michigan Comprehensive Cancer
Center. Percutaneous core needle biopsy was the
primary method of establishing the pathologic diag-
nosis of breast cancer. Diagnostic and therapeutic
management strategies for all patients were reviewed
at the Cancer Center multidisciplinary tumor board
conference. The conduct of this study, with retro-
spective review of all surgical and pathologic records
of appropriate patients, was approved by the Uni-
versity of Michigan Institutional Review Board.
Axillary staging by SLN biopsy performed before
the delivery of neoadjuvant CTX was adopted as a
routine practice by the Breast Oncology Program at
the University of Michigan until approximately
December 2001. From that point forward, the initial
axillary evaluation included ultrasound imaging of the
nodal basin, with ultrasound-guided FNA biopsy of
any abnormal-appearing lymph nodes. If the ultra-
sound imaging was negative for evidence of metasta-
ses, the patient then proceeded to undergo definitive
pre–neoadjuvant CTX axillary staging by SLN biop-
sy. If the patient was found to have axillary metastases
on the basis of either the ultrasound-guided or SLN
biopsy, then she proceeded to receive her neoadjuvant
CTX, but a completion ALND was performed after
the neoadjuvant CTX was delivered, concomitantly
with the definitive breast surgery (lumpectomy or
mastectomy). Lymphatic mapping and SLN biopsy
was performed in conjunction with this completion
ALND. If the definitive pre–neoadjuvant CTX SLN
biopsy had negative results, then the patient pro-
ceeded to receive her neoadjuvant CTX, and no fur-
ther axillary surgery was performed. The neoadjuvant
CTX regimen included doxorubicin in all cases.
Axillary ultrasonography was performed by dedi-
cated breast-imaging staff, and all FNA biopsy results
were interpreted by an experienced cytopathologist.
Lymph nodes were deemed appropriate for ultra-
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sound-guided FNA biopsy if they had irregular mor-
phology (as indicated by cortical thickening), com-
pressed fatty hilum, or complete loss of the fatty hilum.
Lymphatic mapping was performed as a dual-agent
procedure (subareolar 99mTc-labeled sulfur colloid 1
day before surgery and isosulfan blue dye injected
during surgery) as the preferred method unless the
patient specifically declined isotope injection. Five
patients refused the isotope injection in conjunction
with the mapping procedure performed concomitantly
with the ALND after delivery of the neoadjuvant
CTX.The SLNswere evaluated histopathologically by
serial sectioning and hematoxylin and eosin staining;
no immunohistochemistry analyses for cytokeratin
were performed. Non-SLNs were evaluated by stan-
dard bivalving and staining of representative sections.
RESULTS
Overall Study Population
Table 1 shows the clinicopathologic features of the
91 neoadjuvant CTX cases evaluated in this study at
the time of diagnosis.
Node-Negative Patients
Initial pre–neoadjuvant CTX axillary evaluation
consisting of ultrasound imaging and SLN biopsy
was completely negative for evidence of metastatic
disease in 53 cases (58%). These patients underwent
no additional axillary surgery, and at a median fol-
low-up of 14 months (range, 1–39 months), there
have been no locoregional relapses in this subset of
patients with node-negative disease at presentation.
Node-Positive Patients
The final study population consisted of 38 neoad-
juvant CTX patients who were identified as having
node-positive disease at presentation; 18 of the meta-
static nodes were identified by SLN biopsy and 20 by
ultrasound-guided FNA biopsy. For the patients
identified as node positive by SLN biopsy, the median
number of SLNs identified was 3 (range, 1–8), the
median number ofmetastatic SLNswas 1 (range, 1–2),
and the median size of the metastatic focus was 3 mm
(range, 1–5mm). Three of the SLN-positive cases had a
prior negative axillary ultrasound examination, yield-
ing an axillary ultrasound false-negative rate of 17%.
Thirty-three (87%) of these 38 patients underwent
lymphatic mapping in conjunction with the recom-
mended completion ALND after delivery of the
neoadjuvant CTX. Of the remaining five patients, one
refused any additional axillary surgery (this patient
had undergone pre–neoadjuvant CTX SLN biopsy),
and four underwent completion ALND after neoad-
juvant CTX was delivered, but without a follow-up
SLN biopsy. At 2 years follow-up, the patient who
refused additional axillary surgery had no evidence of
locoregional relapse. Of the 4 patients who under-
went ALND without follow-up mapping, 3 had no
residual nodal metastases, and 1 patient had a single
micrometastasis in 1 of 23 nodes.
Completion ALND and Lymphatic Mapping
Of the 33 patients who underwent completion
ALND with follow-up lymphatic mapping, 32 (97%)
of 33 patients underwent a successful SLNbiopsy. One
patient had a failed mapping, with no SLN identifica-
tion. This patient had initially been diagnosed as node
positive by pre–neoadjuvant CTX SLN and had no
residual metastatic disease identified on post-CTX
ALND. There was also no uptake of radioisotope (as
confirmed by a negative preoperative scan) and no blue
dye uptake in this patient. Marked fibrosis was noted
during surgery within the axillary tissue, and patho-
logic assessment revealed an extensive treatment effect.
Aside from this nonidentification case, the median
number of SLNs identified was 3 (range, 1–10). The
median total number of nodes retrieved from the
ALND procedure was 10 (range, 6–35).
Of the 32 successfully mapped cases, 22 (69%) had
residual axillary nodal disease, and 10 (31%) had a
completely negative ALND, with no residual metas-
tases identified. All but 1 of the 22 node-positive cases
included a positive SLN node, for a false-negative
TABLE 1. Clinicopathologic features of the study patient
population (n = 91)
Variable Data
Age, y, median (range) 40 (32–75)
Primary tumor size, cm, median (range) 3.3 (1.5–10)
Histology
Invasive ductal 83 (91%)
Invasive lobular 4 (4%)
Mixed invasive ductal and lobular 4 (4%)
Primary pre–neoadjuvant CTX axillary evaluation
Ultrasound and SLN biopsy results negative 53 (58%)
Axillary node positive 38 (42%)
Ultrasound-guided FNA biopsy 20 (22%)
SLN biopsy positive 18 (20%)
CTX, chemotherapy; SLN, sentinel lymph node biopsy; FNA,
fine-needle aspiration.
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rate of 4.5%. This false-negative case was character-
ized by a single micrometastasis (<2 mm) within one
non-SLN. Of note, there were two cases in which the
residual axillary metastatic disease was limited to the
SLN, and there were no metastatic non-SLNs.
Eleven (33%) of the 33 initially node-positive cases
were free of axillary metastases at the time of com-
pletion ALND performed after their neoadjuvant
CTX. Five of these 11 cases had been diagnosed as
node positive at presentation by pre-CTX SLN
biopsy, and the remainder had axillary metastases
established by ultrasound-guided FNA biopsy.
Results of the post–neoadjuvant CTX lymphatic
mapping stratified by the initial (pre–neoadjuvant
CTX) means of assessing node positivity are listed in
Table 2. The one false-negative case occurred in a
patient whose pre–neoadjuvant CTX node-positive
status had been determined by ultrasound-guided
FNA biopsy. Stratification by method of pre-CTX
nodal biopsy (FNA or SLN) revealed two significant
findings: (1) a repeat post–neoadjuvant CTX SLN
biopsy was feasible in patients who had undergone a
pre–neoadjuvant CTX SLN biopsy (as occurred in 12
of 13 cases), and (2) a complete pathologic nodal
response to neoadjuvant CTX occurred in 30% of
cases (as documented by the absence of nodal
metastases in 6 of the 20 ALND-negative cases that
had previously undergone biopsies by ultrasound-
guided FNA).
DISCUSSION
Lymphatic mapping and SLN biopsy has achieved
rapid acceptance over the past 10 years in the
oncology community as a means of accurately iden-
tifying node-negative patients and sparing them the
morbidity of a standard ALND. Application of this
technology in cases of relatively larger primary breast
tumors has been approached more cautiously because
of concerns that tumor embolization from a bulky
lesion might obstruct and alter lymphatic drainage
pathways. This could contribute to identification of
an incorrect SLN or to a failed mapping procedure.
Findings by Bedrosian et al.16 and Chung et al.,17
however, are quite reassuring. These investigators
reported excellent SLN identification rates (99% and
100%, respectively) and very low false-negative rates
(3% for both studies) in their respective series of 104
patients with tumors at least 3 cm in size and of 41
patients with T3 tumors of the breast.
Patients with relatively larger (but resectable) pri-
mary breast tumors are increasingly being treated
with neoadjuvant CTX, because this sequence im-
proves eligibility for breast preservation via lumpec-
tomy and offers an opportunity to assess sensitivity
versus resistance to the selected systemic therapy
regimen. Although the optimal scenario would be for
appropriately selected patients to reap the benefits of
induction CTX as well as minimally invasive axillary
surgery, it is essential that the multidisciplinary team
adhere to the oncological principles of accurate
staging and maximizing locoregional control of dis-
ease. Because the effects of neoadjuvant CTX on in-
tramammary lymphatics and axillary metastases are
incompletely understood, there has been ongoing
debate regarding the question of whether an SLN
biopsy should be performed before or after the
delivery of induction therapy.
The earliest studies of lymphatic mapping in neo-
adjuvant CTX patients involved SLN biopsy per-
formed in the posttreatment sequence, at the time of
definitive breast surgery. Table 3 tabulates the find-
ings of multiple studies reported to date10,11–14,18–24 in
TABLE 2. Final axillary pathology in the subset of neoadjuvant CTX patients found to be node positive at presentation, stratified
by the initial method of detecting node metastases





FNA (total node-positive cases)
No. of cases 18 20 38
SLN identification rate 12/13 (92%)a 20/20 (100%) 32/33 (97%)
No. of cases with no residual axillary metastases after neoadjuvant CTX 5/13 (38%) 6/20 (30%) 11/33 (33%)
No. of cases with residual axillary metastases after neoadjuvant CTX 8/13 (62%) 14/20 (70%) 22/33 (67%)
No. of cases with residual metastases in SLNs after neoadjuvant CTX 8 13 21
No. of falsely negative SLNs after neoadjuvant CTX 0/8 (0%) 1/14 (7.1%) 1/22 (4.5%)
CTX, chemotherapy; SLN, sentinel lymph node biopsy; FNA, fine-needle aspiration.
a One patient refused additional axillary surgery after delivery of neoadjuvant CTX, and 4 patients underwent completion axillary lymph
node dissection (ALND) only, with no lymphatic mapping; in 1 of 13 cases in which lymphatic mapping was attempted, no sentinel lymph
node was identified.
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which the SLN biopsy was performed with a con-
comitant ALND after neoadjuvant CTX. The first
report, by Breslin et al.,10 from the M.D. Anderson
Cancer Center, revealed the presence of a significant
learning curve, reflecting the additional technical
difficulty of lymphatic mapping related to the CTX
effect on soft tissue in the axilla. A parallel learning
curve is reflected in Table 3; false-negative rates as
high as 33% were seen in some of the earlier studies
with smaller sample sizes, whereas more recent
studies reported no false-negative results. The largest-
scale experience was reported by the National Sur-
gical Adjuvant Breast and Bowel Project B-27 study,
in which more than 400 patients underwent lymphatic
mapping with concomitant ALND after preoperative
doxorubicin and docetaxel treatment. The SLN
identification rate was 85% and the false-negative rate
was 11% in this multicenter study.
Whereas most of the published data regarding SLN
biopsy and neoadjuvant CTX have reported on the
accuracy of lymphatic mapping performed after the
systemic therapy, several breast oncology programs
have adopted the practice of axillary staging with an
SLN biopsy before the delivery of induction CTX.
Table 4 summarizes the results of the reported studies.
Although this sequence subjects the patient to an
additional surgical procedure, it does provide more
definitive information for stratifying the extent of
disease at presentation. The pre–neoadjuvant CTX
SLN biopsy provides only limited information
regarding the full extent of axillary nodal disease, but it
may nonetheless provide useful information tomedical
oncologists in planning CTX regimens for node-posi-
tive versus node-negative disease. Furthermore, radi-
ation oncologists may incorporate this information
into their algorithms for defining potential benefit
from regional irradiation, because current consensus
statements regarding the indications for extended-field
and postmastectomy radiotherapy are applicable only
to patients undergoing surgery as initial therapy.25 The
pre–neoadjuvant CTX lymphatic mapping approach
is technically feasible (as evidenced by the excellent
identification rates); however, accepted practice stan-
dards mandate that patients who are SLN positive
undergo a completion ALND. In the setting of neo-
adjuvant CTX, this completion ALND is typically
TABLE 3. Studies of sentinel lymph node biopsy performed after neoadjuvant chemotherapy
Study T status Sample size
Sentinel node
identification rate False-negative rate
Metastases limited to
sentinel node(s)
Breslin10 (2000) 2, 3 51 85% (42/51) 12% (3/25) 40% (10/25)
Nason12 (2000) 2, 3 15 87% (13/15) 33% (3/9) ‡11%a (‡1/9)
Haid18 (2001) 1–3 33 88% (29/33) 0% (0/22) 50% (11/22)
Fernandez19 (2001) 1–4 40 90% (36/40) 20% (4/20) 20% (4/20)
Tafra34 (2001) 1, 2 29 93% (27/29) 0% (0/15) NR
T4d (inflammatory) 8 75% (6/8) 40% (2/5)
Stearns20 (2002) 3, 4 Noninflammatory 26 88% (23/26) 6% (1/16) 24% (5/21)
Julian13 (2002) 1–3 34 91% (31/34) 0% (0/12) 42% (5/12)
Miller21 (2002) 1–3 35 86% (30/35) 0% (0/9) 44% (4/9)
Brady15 (2002) 1–3 14 93% (13/14) 0% (0/10) 60% (6/10)
Piato35 (2003) 1, 2 42 98% (41/42) 17% (3/18) 0% (0/18)
Balch36 (2003) 2–4 32 97% (31/32) 5% (1/19) 56% (10/18)
Schwartz24 (2003) 1–3 21 100% (21/21) 9% (1/11) 64% (7/11)
Reitsamer37 (2003) 2, 3 30 87% (26/30) 7% (1/15) 53% (8/15)
Mamounas11 (2002) 1–3 428 85% (363/428) 11% (15/140) 50% (70/140)
aEstimated from manuscript.
NR, not reported.
TABLE 4. Results of sentinel lymph node biopsy performed before delivery of neoadjuvant chemotherapy
Pre-CTX SLN biopsy results Post-CTX status
Study Sample size SLN ID rate SLN+ Management strategy
No. of post-CTX ALNDs
negative for residual metastases
Zirngibl38 (2002) 15 14/15 (93%) 6/14 (43%) Completion ALND in
SLN+ patients only
6/6 (100%)
Sabel39 (2003) 24 24/24 (100%) 10/24 (42%) Completion ALND in
SLN+ patients only
3/10 (30%)
Ollila40 (2003) 22 22/22 (100%) 10/22 (45%) Completion ALND in
all patients
12 SLN) patients: 12/12 (100%)
10 SLN+ patients: 6/10 (60%)
CTX, chemotherapy; SLN, sentinel lymph node biopsy; ALND, axillary lymph node dissection.
NEOADJUVANT THERAPY AND AXILLARY EVALUATION 701
Ann. Surg. Oncol. Vol. 12, No. 9, 2005
performed after the delivery of the induction therapy,
concomitantly with the definitive breast operation. A
significant proportionof these completionALNDswill
have completely negative results because the preoper-
ative CTX can sterilize axillary metastases in 25% to
33% of cases26–28 and because metastatic disease is
limited to the SLN(s) in 30% to 50% of cases. It can
therefore be argued that this approach results in some
unnecessary ALNDs.
In our study, 11 (33%) of the initially node-positive
cases were free of axillary disease at the time of
ALND (performed after their neoadjuvant CTX).
Five of these cases were diagnosed by pre-CTX SLN
biopsy. These five patients may have had no addi-
tional metastatic non-SLNs, and we therefore cannot
definitively comment on whether their negative post-
CTX ALND is a consequence of chemoresponse.
Twenty patients were established as being node po-
sitive on the basis of an ultrasound-guided FNA; six
(30%) of these patients had no residual metastatic
nodes in their ALND specimens. This subset does
represent the axillary complete response group, and
this rate of CTX effect on axillary metastases is
consistent with other studies of nodal chemosensi-
tivity.
One of the major benefits of neoadjuvant CTX is
the ability to rapidly assess disease chemosensitivity.
Patients who experience a complete pathologic re-
sponse have a statistically superior outcome,29,30
thereby confirming that primary tumor response is an
excellent surrogate marker for CTX effect on sys-
temic micrometastases. Studies of neoadjuvant CTX
have also suggested that pathologic response specifi-
cally within axillary metastases is an independent
predictor of outcome.26,28,31 It is therefore beneficial
to be able to distinguish the patients who are node
negative at presentation from those whose axillary
metastases were sterilized by the induction CTX.
Our study demonstrates that by using a compre-
hensive and sequential approach to evaluating the
axilla, the benefits of pre–neoadjuvant CTX and post–
neoadjuvant CTX staging can be maximized while
subjecting the fewest patients to the morbidity of an
ALND. Axillary ultrasonography can be readily
incorporated into the baseline imaging of newly diag-
nosed breast cancer patients and can then reliably
guide the radiologist to an appropriate lymph node for
FNA biopsy. Malignant cytopathology on FNA
biopsy will reliably stage a patient as havingmetastatic
axillary disease, and in these cases an SLN biopsy will
be unnecessary. In contrast, published data reveal that
axillary ultrasound can be falsely negative in 20% of
cases,32,33 and a definitive SLN biopsy is required to
avoid understaging the patients disease. Patients who
are definitively proven to be node negative at presen-
tation can then proceed to receive their neoadjuvant
CTX for primary breast tumor downstaging, and no
additional axillary surgery is necessary.
It might be argued that there is limited benefit to
performing the pre-neoadjuvant CTX SLN biopsy in
the minority of cases in which the axillary ultra-
sound is falsely negative, especially because these
will frequently be cases of metastatic foci <5 mm.
However, the approximately 20% false-negative rate
of axillary ultrasound is not trivial. For multi-
disciplinary breast oncology practices in which the
teams systemic therapy or adjuvant radiotherapy
recommendations are influenced by the nodal status
before neoadjuvant CTX, an SLN biopsy will re-
main necessary to establish node negativity after an
axillary ultrasound examination with negative re-
sults. Furthermore, many institutions will not have
radiologists who are experienced with axillary ul-
trasonography, and a pre–neoadjuvant CTX SLN
biopsy will be the only way to definitively stage the
axilla at presentation.
Patients identified as having metastatic axillary
disease at presentation (by either FNA or SLN
biopsy) proceed to receive their neoadjuvant CTX,
but the axilla should be reevaluated pathologically
for evidence of residual disease after neoadjuvant
CTX. Our findings are consistent with other studies
in demonstrating that the induction therapy will
sterilize a substantial fraction of nodal metastases. In
our study, one third of cases were completely node
negative after neoadjuvant CTX. Furthermore, we
found that a follow-up SLN biopsy performed in the
post–neoadjuvant CTX setting was a feasible and
accurate means of identifying the patients with no
residual axillary metastases. If our findings are vali-
dated by others, then deferral of the completion
ALND should be considered; this approach may save
an additional 30% of patients from having to face the
morbidity of an ALND.
Future studies should be designed to corroborate
our findings. Furthermore, postneoadjuvant axillary
ultrasonography should also be considered, because
this may represent a minimally invasive means of
identifying patients who do harbor residual axillary
metastases.
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